QNCX

$0.10

Post-MarketAs of Mar 17, 8:00 PM UTC

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.10
Potential Upside
5%
Whystock Fair Value$0.10
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of ra...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.27
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-247.78%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.05

Recent News

Associated Press Finance
Mar 5, 2026

BC-Most Active Stocks

Elong Power Holding Ltd. 329,453,698 0.1034

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Clinical Trials Arena
Feb 2, 2026

Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure

Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
The Fly
Jan 30, 2026

Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls

Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Dec 16, 2025

Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital

D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump. Claim 50% Off TipRanks Premium and Invest with Confidenc

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jun 16, 2025

June 2025's Promising Penny Stocks For Savvy Investors

As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.